Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
auranofin + sirolimus
- Development stage
- Phase 2
- Lead developer
- Mayo Clinic
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination involves **auranofin**, a gold-containing compound traditionally used for rheumatoid arthritis, and **sirolimus**, an immunosuppressant that inhibits the mammalian target of rapamycin (mTOR). The combination is being explored for its potential in treating various cancers, including lung cancer and ovarian cancer, by modulating immune responses and inhibiting tumor growth.
02
Targets
TXNRD2 (Thioredoxin reductase 2)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on auranofin + sirolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on auranofin + sirolimus.